China Medical System Holdings Limited (SGX:8A8)

Market Cap	4.34B +30.1%
Revenue (ttm)	1.51B +9.9%
Net Income	273.80M -8.1%
EPS	0.11 -7.8%
Shares Out	n/a
PE Ratio	15.84
Forward PE	11.46
Dividend	0.05 (2.93%)
Ex-Dividend Date	Apr 28, 2026

Volume	6,200
Average Volume	8,215
Open	1.830
Previous Close	1.830
Day's Range	1.810 - 1.830
52-Week Range	1.810 - 2.550
Beta	n/a
RSI	24.16
Earnings Date	May 22, 2026

About SGX:8A8

China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People’s Republic of China. The company offers cardio-cerebrovascular products include VELPHORO, a sucroferric oxyhydroxide chewable tablets and diazepam nasal spray for seizure clusters; XinHuoSu, a recombinant human brain natriuretic peptide for acute heart failure; Plendil, a felodipine sustained release tablets for hypertension; and Deanxit, a flupentixol and melitracen tablets for mild-to-moderate ...

• Industry: Pharmaceutical Preparations
• Founded: 1995
• Employees: 6,415
• Stock Exchange: Singapore Exchange
• Ticker Symbol: 8A8

Financial Performance

In 2025, SGX:8A8's revenue was 8.21 billion, an increase of 9.95% compared to the previous year's 7.47 billion. Earnings were 1.49 billion, a decrease of -8.08%.

Financial numbers in CNY